Skip to main content

CARACTERIZACION Y REPERCUSION TERAPEUTICA DE LA ECOLOGIA DE CANCER DE MAMA HER2 POSITIVO

PI18/01219

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2018
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION HOSPITAL CLINICO UNIVERSITARIO DE VALENCIA
Execution centre INSTITUTO DE INVESTIGACION SANITARIA INCLIVA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

  • Adam-Artigues, Anna|||0000-0002-4257-8535
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Martínez-Sabadell, Alex|||0000-0002-9477-1396
  • Brasó-Maristany, Fara|||0000-0001-5440-9643
  • Cervera Vidal, Raimundo|||0000-0002-8213-4058
  • Tormo, Eduardo
  • Hernando Davalillo, Cristina
  • Martínez Martínez, María Teresa|||0000-0003-1312-3555
  • Carbonell Asins, Juan Antonio|||0000-0002-8449-5674
  • Simón, Soraya
  • Poveda Ferriols, Jesús Manuel|||0000-0002-9785-0997
  • Moragón, Santiago|||0000-0001-6490-6977
  • Zazo, Sandra
  • Martínez, Débora
  • Rovira, Ana|||0000-0003-1301-2599
  • Burgués, Octavio|||0000-0002-2471-5516
  • Rojo, Federico|||0000-0001-9989-0290
  • Albanell Mestres, Joan|||0000-0003-1239-4580
  • Bermejo, Begoña
  • Lluch, Ana|||0000-0003-2766-407X
  • Prat, Aleix|||0000-0003-2377-540X
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Eroles, Pilar|||0000-0003-2708-6206
  • Cejalvo, Juan Miguel|||0000-0002-8755-8626
Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer. However, different mechanisms play a role in treatment resistance. Here, we identified AXL overexpression as an essential mechanism of trastuzumab resistance. AXL orchestrates epithelial-to-mesenchymal transition and heterodimerizes with HER2, leading to activation of PI3K/AKT and MAPK pathways in a ligand-independent manner. Genetic depletion and pharmacological inhibition of AXL restored trastuzumab response in vitro and in vivo. AXL inhibitor plus trastuzumab achieved complete regression in trastuzumab-resistant patient-derived xenograft models. Moreover, AXL expression in HER2-positive primary tumors was able to predict prognosis. Data from the PAMELA trial showed a change in AXL expression during neoadjuvant dual HER2 blockade, supporting its role in resistance. Therefore, our study highlights the importance of targeting AXL in combination with anti-HER2 drugs across HER2-amplified breast cancer patients with high AXL expression. Furthermore, it unveils the potential value of AXL as a druggable prognostic biomarker in HER2-positive breast cancer. AXL is a prognostic biomarker and a potential therapeutic target to restore trastuzumab response in HER2 + breast cancer.